July 1, 2025 · Form 4 insider transaction
Kiselak Tomas bought 21,000 shares of Viridian Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.; Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.